Cabio Biotech (Wuhan) Income Statement

Financials in millions CNY. Fiscal year is January - December.

Millions CNY. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar '26 Mar 31, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Operating Revenue	418.18	563.14	542.29	435.39	402.08	350.76
Other Revenue	-	-	13.31	8.41	31.35	0.35
Revenue	418.18	563.14	555.59	443.8	433.42	351.11
Revenue Growth (YoY)	-29.66%	1.36%	25.19%	2.40%	23.44%	8.55%
Cost of Revenue	236.65	294.54	326.81	264.51	257.14	172.33
Gross Profit	181.53	268.6	228.78	179.29	176.29	178.78
Selling, General & Admin	69.75	68.09	72.35	56.34	64.32	42.18
Research & Development	48.69	47.39	47.57	38.23	31.84	30.54
Other Operating Expenses	0.31	-0.21	5.36	6.38	4.56	5.01
Operating Expenses	118.74	115.27	125.82	103.21	111.93	77.08
Operating Income	62.79	153.33	102.97	76.08	64.35	101.7
Interest Expense	-1.19	-	-0.4	-0.6	-0.37	-0.35
Interest & Investment Income	-	3.44	3.52	7.41	7.12	16.83
Currency Exchange Gain (Loss)	-	-	2.78	1.08	11.28	-2.6
Other Non Operating Income (Expenses)	18.56	24.1	-2.31	26.37	23.94	34.41
EBT Excluding Unusual Items	80.16	180.87	106.56	110.34	106.33	149.99
Gain (Loss) on Sale of Investments	-0.34	-4.47	0.27	-2.64	-37.8	0.99
Gain (Loss) on Sale of Assets	-	-	-0	0.05	0	-2.4
Asset Writedown	-14.37	-14.1	-5.21	-4.13	-0.69	-
Other Unusual Items	-	-	38.21	-3.62	10.29	3.48
Pretax Income	65.44	162.3	139.82	100	78.14	152.06
Income Tax Expense	15.65	23	19.69	13.63	16.56	20.77
Earnings From Continuing Operations	49.79	139.29	120.13	86.37	61.58	131.29
Minority Interest in Earnings	5.37	4.43	4.08	5.01	2.79	-2.72
Net Income	55.16	143.72	124.21	91.37	64.37	128.58
Net Income to Common	55.16	143.72	124.21	91.37	64.37	128.58
Net Income Growth	-61.93%	15.71%	35.94%	41.95%	-49.94%	-1.54%
Shares Outstanding (Basic)	167	167	168	169	169	168
Shares Outstanding (Diluted)	167	167	168	169	169	168
Shares Change (YoY)	0.75%	-0.44%	-0.80%	-0.11%	0.69%	0.31%
EPS (Basic)	0.33	0.86	0.74	0.54	0.38	0.76
EPS (Diluted)	0.33	0.86	0.74	0.54	0.38	0.76
EPS Growth	-62.21%	16.22%	37.04%	42.10%	-50.28%	-1.84%
Free Cash Flow	97.13	125.53	-38.55	-228.79	-73.07	-70.14
Free Cash Flow Per Share	0.58	0.75	-0.23	-1.35	-0.43	-0.42
Dividend Per Share	-	-	0.201	0.200	0.214	0.236
Dividend Growth	-	-	0.47%	-6.67%	-9.08%	-
Gross Margin	43.41%	47.70%	41.18%	40.40%	40.67%	50.92%
Operating Margin	15.02%	27.23%	18.53%	17.14%	14.85%	28.97%
Profit Margin	13.19%	25.52%	22.36%	20.59%	14.85%	36.62%
Free Cash Flow Margin	23.23%	22.29%	-6.94%	-51.55%	-16.86%	-19.98%
EBITDA	126.13	214.84	157.22	123.14	90.4	125.02
EBITDA Margin	30.16%	38.15%	28.30%	27.74%	20.86%	35.61%
D&A For EBITDA	63.33	61.52	54.25	47.06	26.04	23.32
EBIT	62.79	153.33	102.97	76.08	64.35	101.7
EBIT Margin	15.02%	27.23%	18.53%	17.14%	14.85%	28.97%
Effective Tax Rate	23.92%	14.17%	14.08%	13.63%	21.19%	13.66%
Revenue as Reported	-	-	555.59	443.8	433.42	351.11
Advertising Expenses	-	-	6.61	5.28	2.27	1.11

Source: S&P Global Market Intelligence. Standard template. Financial Sources.